SignalEarnings
Vertex Q3 Earnings Call Highlights Revenue Beat and Pipeline Expansion
Vertex Q3 Earnings Call Highlights Revenue Beat and Pipeline Expansion
Context
What happened: Vertex Pharmaceuticals ($VRTX) reported third-quarter 2026 revenue growth of 12% year over year, driven by its cystic fibrosis franchise and newer therapies, and raised its full-year revenue guidance following the Crinetics Pharmaceuticals acquisition.
Key numbers: Revenue $3.44 billion vs.
Why it matters: Higher operating expenses and Crinetics acquisition costs weighed on profitability, and management flagged that financing and integration costs could continue affecting near-term earnings. The raised guidance includes an anticipated $40-$50 million PALSONIFY contribution.
Market: -4.0% today ($530.76), +17.4% YTD, 1.5x vol — as of 22:46 UTC
Verified: Q3_2026 (Nov 2) EPS $4.76 vs $4.75 est, +0.2% beat; next print ~Feb 1
Coverage: 3 outlets in 24h
What changed
Vertex Pharmaceuticals ($VRTX) reported third-quarter 2026 revenue growth of 12% year over year, driven by its cystic fibrosis franchise and newer therapies, and raised its full-year revenue guidance following the Crinetics Pharmaceuticals acquisition.
Why it matters
Higher operating expenses and Crinetics acquisition costs weighed on profitability, and management flagged that financing and integration costs could continue affecting near-term earnings. The raised guidance includes an anticipated $40-$50 million PALSONIFY contribution.
Market: -4.0% today ($530.76), +17.4% YTD, 1.5x vol — as of 22:46 UTC
Verified: Q3_2026 (Nov 2) EPS $4.76 vs $4.75 est, +0.2% beat; next print ~Feb 1